Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eczema drug upadacitinib under Real-World safety check in china

NCT ID NCT05959083

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how safe and effective upadacitinib is for Chinese adolescents and adults with moderate to severe atopic dermatitis (eczema). About 200 participants will take the drug as prescribed by their doctor and be followed for up to 24 months. The goal is to track serious infections and other side effects in real-world use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
upadacitinib
What this could lead to
If successful, this could confirm that upadacitinib is a safe and effective option for managing moderate to severe atopic dermatitis in Chinese patients.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It only includes Chinese patients, so findings may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

200 people

The number who actually took part.

Started

Aug 2023

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adolescent and adult Chinese participants with atopic dermatitis (AD) who are prescribed Upadacitinib by their physician according to their local label.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of moderate to severe atopic dermatitis (AD) at the time of enrollment. * Chinese adolescents (≥12 to \<18 years of age with body weight of ≥40 kg) or adults (≥18 years of age) at the time of enrollment. * Participants eligible for initiation of Upadacitinib treatment for AD, including any required screening tests indicated per China Label. * The decision to prescribe Upadacitinib is made prior to and independently of study participation. Exclusion Criteria: * Participants who cannot be treated with Upadacitinib as per China label or by judgement of treating physician. * Currently participating in any interventional research studies.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis (AD)

Contacts and locations

Locations

  • Chengdu Second Municipal People's Hospital /ID# 257732

    Chengdu, Sichuan, 610017, China

  • Dermatology Hospital of Southern Medical University /ID# 261862

    Guangzhou, Guangdong, 510091, China

  • First Affiliated Hospital of China Medical University /ID# 257641

    Shenyang, Liaoning, 110001, China

  • Hangzhou First People's Hospital /ID# 261867

    Hangzhou, Zhejiang, 310003, China

  • Huashan Hospital, Fudan University /ID# 256456

    Shanghai, Shanghai Municipality, 200040, China

  • Ningbo First Hospital /ID# 263884

    Ningbo, Zhejiang, 315010, China

  • Peking University Third Hospital /ID# 257722

    Beijing, Beijing Municipality, 100191, China

  • People's Hospital of Henan Province /ID# 257736

    Zhengzhou, Henan, 450003, China

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 257726

    Shanghai, Shanghai Municipality, 200065, China

  • Second Affiliated Hospital of Xian Jiaotong University /ID# 257733

    Xi'an, Shaanxi, 710004, China

  • Shandong Dermatological Hospital /ID# 257727

    Jinan, Shandong, 250022, China

  • Shanghai Skin Disease Hospital /ID# 257719

    Shanghai, Shanghai Municipality, 200443, China

  • Sichuan Provincial People's Hospital /ID# 263898

    Chengdu, Sichuan, 610072, China

  • The Eighth Affiliated Hospital, Sun Yat-sen universtiy /ID# 257737

    Shenzhen, Guangdong, 518033, China

  • The First Affiliated Hospital Of Fujian Medical University /ID# 257725

    Fuzhou, Fujian, 350005, China

  • The Second Affiliated Hospital of Zhejiang University School of Medicine /ID# 257723

    Hangzhou, Zhejiang, 310009, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 257724

    Wuhan, Hubei, 430022, China

  • West China Hospital, Sichuan University /ID# 257720

    Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.